keyword
MENU ▼
Read by QxMD icon Read
search

Severe treatment resistant major depression

keyword
https://www.readbyqxmd.com/read/29438781/neurobiological-links-between-depression-and-ad-the-role-of-tgf-%C3%AE-1-signaling-as-a-new-pharmacological-target
#1
REVIEW
Filippo Caraci, Simona Federica Spampinato, Maria Grazia Morgese, Fabio Tascedda, Maria Grazia Salluzzo, Maria Concetta Giambirtone, Giuseppe Caruso, Antonio Munafò, Sebastiano Alfio Torrisi, Gian Marco Leggio, Luigia Trabace, Ferdinando Nicoletti, Filippo Drago, Maria Angela Sortino, Agata Copani
In the last several years a large number of studies have demonstrated the neurobiological and clinical continuum between depression and Alzheimer's disease (AD). Depression is a risk factor for the development of AD, and the presence of depressive symptoms significantly increases the conversion of Mild Cognitive Impairment (MCI) into AD. Common pathophysiological events have been identified in depression and AD, including neuroinflammation with an aberrant Tumor Necrosis Factor-α (TNF-α) signaling, and an impairment of Brain-Derived Neurotrophic Factor (BDNF) and Transforming-Growth-Factor-β1 (TGF-β1) signaling...
February 10, 2018: Pharmacological Research: the Official Journal of the Italian Pharmacological Society
https://www.readbyqxmd.com/read/29411705/-vascular-endothelial-growth-factor-vegf-as-a-potential-biomarker-in-major-depressive-disorder
#2
Monika Elemery, Szilvia Kiss, Xenia Gonda, Peter Dome, Judit Lazary
BACKGROUND: There is growing evidence that vascular endothelial growth factor (VEGF) plays a crucial role in neurodevelopment and regeneration. Several data support that intact VEGF pathway is indispensable for therapeutic effect of antidepressants, any disruption of VEGF signaling can result treatment resistance. In our study we investigated the peripherial blood VEGF level before and 4-week after antidepressant treatment in patients with major depressive episode and we compared VEGF levels between responders and non-responders...
December 2017: Neuropsychopharmacologia Hungarica
https://www.readbyqxmd.com/read/29389676/decreased-cognitive-functioning-after-electroconvulsive-therapy-is-related-to-increased-hippocampal-volume-exploring-the-role-of-brain-plasticity
#3
Iris van Oostrom, Philip van Eijndhoven, Elke Butterbrod, Maria H van Beek, Joost Janzing, Rogier Donders, Aart Schene, Indira Tendolkar
OBJECTIVE: Electroconvulsive therapy (ECT) is still the most effective treatment of severe and therapy-refractory major depressive disorder. Cognitive side effects are the major disadvantage of ECT. Cognitive deficits are generally temporary in nature and may be mediated by the hippocampus. Recent studies have shown a temporary increase in hippocampal volume and a temporary decrease in cognitive functioning post-ECT compared with pre-ECT. This study investigates whether these volumetric changes are related to changes in cognitive functioning after ECT...
January 31, 2018: Journal of ECT
https://www.readbyqxmd.com/read/29388201/benefits-of-and-barriers-to-pharmacogenomics-guided-treatment-for-major-depressive-disorder
#4
Ahmed T Ahmed, Richard Weinshilboum, Mark A Frye
Antidepressants have reduced the symptom burden for many Major Depressive Disorder (MDD) patients, but drug-related side effects and treatment resistance continue to present major challenges. Pharmacogenomics represents one approach to enhance antidepressant efficacy and avoid adverse reactions, but concerns remain with regard to the overall "value equation," and several barriers must be overcome to achieve the full potential of MDD pharmacogenomics.
February 1, 2018: Clinical Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/29372569/intravenous-ketamine-infusion-for-a-patient-with-treatment-resistant-major-depression-a-10-month-follow-up
#5
J H Kwon, W S Sim, J P Hong, I S Song, J Y Lee
WHAT IS KNOWN AND OBJECTIVE: Ketamine in a subanaesthetic dose has been shown to produce rapid antidepressant effects. Here, we describe a long-term follow-up case of a Korean patient with severe major depression who received repeated ketamine intravenous therapy (KIT). CASE DESCRIPTION: A 49-year-old woman with a 6-year history of treatment-resistant major depression was given KIT once every 1 or 2 weeks over 10 months, for a total of 36 treatments. Her mood stabilized, and she showed a nearly 50% reduction in the severity of her depressive symptom...
January 25, 2018: Journal of Clinical Pharmacy and Therapeutics
https://www.readbyqxmd.com/read/29370485/validity-of-the-maudsley-staging-method-in-predicting-treatment-resistant-depression-outcome-using-the-netherlands-study-of-depression-and-anxiety
#6
Sjoerd M van Belkum, Hanneke H Geugies, Thom S Lysen, Anthony J Cleare, Frenk P M L Peeters, Brenda W J H Penninx, Robert A Schoevers, Eric G Ruhe
OBJECTIVE: We investigated if the degree of treatment resistance of depression, as measured by the Maudsley Staging Method (MSM), is predictive of a worse depression outcome by using a large naturalistic cohort of depressed patients. METHODS: 643 subjects from the general population, primary care, and secondary care who suffered from current depressive disorder were included from the Netherlands Study of Depression and Anxiety baseline assessment. The diagnostic criterion was major depressive disorder (MDD) in the last month, based on the Composite Interview Diagnostic Instrument (CIDI), or a CIDI diagnosis of MDD in the past 6 months with an Inventory of Depressive Symptomatology Self-Report score > 24 at baseline...
January 23, 2018: Journal of Clinical Psychiatry
https://www.readbyqxmd.com/read/29360650/exploring-nitrous-oxide-as-treatment-of-mood-disorders-basic-concepts
#7
Peter Nagele, Charles F Zorumski, Charles Conway
Nitrous oxide (laughing gas) has shown early promise as a rapidly acting antidepressant in patients with treatment-resistant major depression and is currently investigated in several clinical trials. Because nitrous oxide is rarely administered outside operating rooms or dental practices, most psychiatrists are not familiar with how nitrous oxide is administered in a medical setting and what regulations guide its use. The goal of this brief review was to educate psychiatrists about the basic concepts of nitrous oxide administration and pharmacology...
January 23, 2018: Journal of Clinical Psychopharmacology
https://www.readbyqxmd.com/read/29282469/efficacy-and-safety-of-intranasal-esketamine-adjunctive-to-oral-antidepressant-therapy-in-treatment-resistant-depression-a-randomized-clinical-trial
#8
Ella J Daly, Jaskaran B Singh, Maggie Fedgchin, Kimberly Cooper, Pilar Lim, Richard C Shelton, Michael E Thase, Andrew Winokur, Luc Van Nueten, Husseini Manji, Wayne C Drevets
Importance: Approximately one-third of patients with major depressive disorder (MDD) do not respond to available antidepressants. Objective: To assess the efficacy, safety, and dose-response of intranasal esketamine hydrochloride in patients with treatment-resistant depression (TRD). Design, Setting, and Participants: This phase 2, double-blind, doubly randomized, delayed-start, placebo-controlled study was conducted in multiple outpatient referral centers from January 28, 2014, to September 25, 2015...
February 1, 2018: JAMA Psychiatry
https://www.readbyqxmd.com/read/29275697/the-economic-cost-of-treatment-resistant-depression-in-patients-referred-to-a-specialist-service
#9
Paul McCrone, Felicitas Rost, Leonardo Koeser, Iakovina Koutoufa, Stephanie Stephanou, Martin Knapp, David Goldberg, David Taylor, Peter Fonagy
BACKGROUND: Patients with treatment-resistant depression (TRD) suffer very significant morbidity and are at a disadvantage concerning optimal clinical management. There are high associated societal costs. AIMS: A detailed analysis of health economic costs in the United Kingdom in a group manifesting a severe form of TRD in the 12 months before their participation in a major randomized controlled treatment trial. METHODS: The sample consisted of 118 participants from the Tavistock Adult Depression Study...
December 23, 2017: Journal of Mental Health
https://www.readbyqxmd.com/read/29273063/nitrous-oxide-n2o-and-subsequent-open-label-ssri-treatment-of-adolescents-with-depression-notad-study-protocol-for-a-randomised-controlled-trial
#10
Richard M Stewart, Janice W Y Wong, Kevin C Runions, Pradeep Rao, Julia K Moore, Simon R Davies, Britta S von Ungern-Sternberg, David Sommerfield, Florian Daniel Zepf
BACKGROUND: The first line of pharmacological treatment for severe depressive disorders in young people is selective serotonin reuptake inhibitors (SSRIs). However, beneficial clinical effects are rarely observed before several weeks into treatment. Nitrous oxide (N2O) has a long-standing safety record for pain relief and has been used in adults and young people. In adults with severe treatment-resistant depression, a single dose of N2O had significant antidepressant effects, with maximum antidepressant effects observed 24 h after administration...
December 22, 2017: Trials
https://www.readbyqxmd.com/read/29235659/effect-of-metabolic-syndrome-on-late-life-depression-associations-with-disease-severity-and-treatment-resistance
#11
RANDOMIZED CONTROLLED TRIAL
John S Mulvahill, Ginger E Nicol, David Dixon, Eric J Lenze, Jordan F Karp, Charles F Reynolds, Daniel M Blumberger, Benoit H Mulsant
BACKGROUND/OBJECTIVES: Metabolic syndrome (MetS) is the co-occurrence of obesity and metabolic derangements. Prior research implicates MetS in prolongation of the course of depression in older adults, but its effect on antidepressant response is unknown in this population. The objective was to determine whether MetS and related metabolic dyscrasias are associated with decreased rate of remission from depression in older adults treated pharmacologically for depression. DESIGN: Secondary analysis of a randomized controlled trial...
December 2017: Journal of the American Geriatrics Society
https://www.readbyqxmd.com/read/29228516/refining-prediction-in-treatment-resistant-depression-results-of-machine-learning-analyses-in-the-trd-iii-sample
#12
Alexander Kautzky, Markus Dold, Lucie Bartova, Marie Spies, Thomas Vanicek, Daniel Souery, Stuart Montgomery, Julien Mendlewicz, Joseph Zohar, Chiara Fabbri, Alessandro Serretti, Rupert Lanzenberger, Siegfried Kasper
OBJECTIVE: The study objective was to generate a prediction model for treatment-resistant depression (TRD) using machine learning featuring a large set of 47 clinical and sociodemographic predictors of treatment outcome. METHOD: 552 Patients diagnosed with major depressive disorder (MDD) according to DSM-IV criteria were enrolled between 2011 and 2016. TRD was defined as failure to reach response to antidepressant treatment, characterized by a Montgomery-Asberg Depression Rating Scale (MADRS) score below 22 after at least 2 antidepressant trials of adequate length and dosage were administered...
December 5, 2017: Journal of Clinical Psychiatry
https://www.readbyqxmd.com/read/29225582/significant-need-for-a-french-network-of-expert-centers-enabling-a-better-characterization-and-management-of-treatment-resistant-depression-fondation-fondamental
#13
Antoine Yrondi, Djamila Bennabi, Emmanuel Haffen, Marion Garnier, Frank Bellivier, Thierry Bourgerol, Vincent Camus, Thierry D'Amato, Olivier Doumy, Frédéric Haesebaert, Jérôme Holtzmann, Christophe Lançon, Philippe Vignaud, Fanny Moliere, Isabel Nieto, Raphaëlle Marie Richieri, Philippe Domenech, Corentin Rabu, Luc Mallet, Liova Yon, Laurent Schmitt, Florian Stephan, Guillaume Vaiva, Michel Walter, Pierre-Michel Llorca, Philippe Courtet, Marion Leboyer, Wissam El-Hage, Bruno Aouizerate
Background: Major depression is characterized by (i) a high lifetime prevalence of 16-17% in the general population; (ii) a high frequency of treatment resistance in around 20-30% of cases; (iii) a recurrent or chronic course; (iv) a negative impact on the general functioning and quality of life; and (v) a high level of comorbidity with various psychiatric and non-psychiatric disorders, high occurrence of completed suicide, significant burden along with the personal, societal, and economic costs...
2017: Frontiers in Psychiatry
https://www.readbyqxmd.com/read/29179735/ficus-sycomorus-extract-reversed-behavioral-impairment-and-brain-oxidative-stress-induced-by-unpredictable-chronic-mild-stress-in-rats
#14
Harquin Simplice Harquin Foyet, Serge Tchinda Deffo, Pascaline Koagne Yewo, Iulia Antioch, Stéphane Zingue, Emmanuel Acha Asongalem, Pierre Kamtchouing, Alin Ciobica
BACKGROUND: Stress, regardless of its nature is nowadays recognized as one of the major risk factors for neuropsychiatric diseases, such as mood and anxiety disorders. The brain compared with other organs is more vulnerable to oxidative damage mainly due to its high rate of oxygen consumption, abundant lipid content, and relative insufficiency of antioxidant enzymes. Thus, the identification of neural mechanisms underlying resistance and vulnerability to stress is of crucial importance in understanding the pathophysiology of neuropsychiatric disorders and in developing new treatments, since the existing ones are for several reasons subject to increasing limitations...
November 28, 2017: BMC Complementary and Alternative Medicine
https://www.readbyqxmd.com/read/29166316/the-impact-of-repetitive-transcranial-magnetic-stimulation-on-oxidative-stress-in-subjects-with-medication-resistant-depression
#15
Onur Durmaz, Emre İspir, Hayriye Baykan, Murat Alişik, Özcan Erel
OBJECTIVES: Recent studies have shown that oxidative stress is involved in the neurobiology of depression. We investigated the effects of repetitive transcranial magnetic stimulation (rTMS) on a novel oxidative stress marker, thiol-disulfide homeostasis, in subjects with medication-resistant major depression (MRD). METHODS: Twenty-six subjects with MRD underwent 15 rTMS sessions. Sociodemographic and baseline and post-rTMS Montgomery-Asberg Depression Rating Scale (MADRS) data were collected...
November 21, 2017: Journal of ECT
https://www.readbyqxmd.com/read/29119217/psilocybin-with-psychological-support-for-treatment-resistant-depression-six-month-follow-up
#16
R L Carhart-Harris, M Bolstridge, C M J Day, J Rucker, R Watts, D E Erritzoe, M Kaelen, B Giribaldi, M Bloomfield, S Pilling, J A Rickard, B Forbes, A Feilding, D Taylor, H V Curran, D J Nutt
RATIONALE: Recent clinical trials are reporting marked improvements in mental health outcomes with psychedelic drug-assisted psychotherapy. OBJECTIVES: Here, we report on safety and efficacy outcomes for up to 6 months in an open-label trial of psilocybin for treatment-resistant depression. METHODS: Twenty patients (six females) with (mostly) severe, unipolar, treatment-resistant major depression received two oral doses of psilocybin (10 and 25 mg, 7 days apart) in a supportive setting...
November 8, 2017: Psychopharmacology
https://www.readbyqxmd.com/read/29115994/exploring-venlafaxine-pharmacokinetic-variability-with-a-phenotyping-approach-a-multicentric-french-swiss-study-marvel-study
#17
Célia Lloret-Linares, Youssef Daali, Sylvie Chevret, Isabelle Nieto, Fanny Molière, Philippe Courtet, Florence Galtier, Raphaëlle-Marie Richieri, Sophie Morange, Pierre-Michel Llorca, Wissam El-Hage, Thomas Desmidt, Frédéric Haesebaert, Philippe Vignaud, Jerôme Holtzmann, Jean-Luc Cracowski, Marion Leboyer, Antoine Yrondi, Fabienne Calvas, Liova Yon, Philippe Le Corvoisier, Olivier Doumy, Kyle Heron, Damien Montange, Siamak Davani, Julien Déglon, Marie Besson, Jules Desmeules, Emmanuel Haffen, Frank Bellivier
BACKGROUND: It is well known that the standard doses of a given drug may not have equivalent effects in all patients. To date, the management of depression remains mainly empirical and often poorly evaluated. The development of a personalized medicine in psychiatry may reduce treatment failure, intolerance or resistance, and hence the burden and costs of mood depressive disorders. The Geneva Cocktail Phenotypic approach presents several advantages including the "in vivo" measure of different cytochromes and transporter P-gp activities, their simultaneous determination in a single test, avoiding the influence of variability over time on phenotyping results, the administration of low dose substrates, a limited sampling strategy with an analytical method developed on DBS analysis...
November 7, 2017: BMC Pharmacology & Toxicology
https://www.readbyqxmd.com/read/29111404/a-systematic-review-and-meta-analysis-on-placebo-response-to-repetitive-transcranial-magnetic-stimulation-for-depression-trials
#18
Laís B Razza, Adriano H Moffa, Marina L Moreno, Andre F Carvalho, Frank Padberg, Felipe Fregni, André R Brunoni
BACKGROUND: Although several studies indicate that placebo response is large to antidepressant pharmacotherapy in major depressive disorder (MDD), no updated meta-analysis has quantified the magnitude of the placebo (sham) response to repetitive transcranial magnetic stimulation (rTMS) in MDD yet. OBJECTIVE: To conduct a systematic review and meta-analysis on this issue in randomized controlled trials (RCTs) involving participants with MDD; and to explore potential moderators...
February 2, 2018: Progress in Neuro-psychopharmacology & Biological Psychiatry
https://www.readbyqxmd.com/read/29106789/depression-and-obstructive-sleep-apnea
#19
(no author information available yet)
OBJECTIVE: Obstructive sleep apnea (OSA), is described as intermittent interruptions or reductions in airflow which are initiated by an incomplete or complete collapse of the upper airways despite respiratory effort. When left untreated, OSA is connected with comorbid conditions, such as cardiovascular and metabolic illnesses. METHOD: The PubMed database was used to examine papers published until April 2017 using the subsequent terms: "obstructive sleep apnea" or "obstructive sleep apnoea" and "depression" in successive combination with "CPAP (continuous positive airway pressure)", "therapy", "pharmacotherapy", "psychotherapy", "cognitive behavioral therapy" or "quality of life"...
October 6, 2017: Neuro Endocrinology Letters
https://www.readbyqxmd.com/read/29101798/cytokine-serum-levels-remain-unchanged-during-lithium-augmentation-of-antidepressants-in-major-depression
#20
Roland Ricken, Marlene Busche, Peter Schlattmann, Hubertus Himmerich, Sandra Bopp, Tom Bschor, Christoph Richter, Thomas J Stamm, Andreas Heinz, Rainer Hellweg, Undine E Lang, Mazda Adli
Lithium augmentation (LA) of antidepressants is a first-line therapy in treatment-resistant depression. Immunomodulatory effects of lithium have been described. The cytokine hypothesis of depression postulates that cytokines play a key role in the pathophysiology of depression. Concordantly, it has been shown that proinflammatory cytokine serum levels decrease during antidepressant treatment. The aim of this study was to investigate changes in cytokine serum levels during LA. Serum concentrations of the cytokines interleukin (IL)-2, IL-4, IL-6, IL-8, IL-10, tumour necrosis factor alpha, interferon-gamma, granulocyte and monocyte colony stimulating factor were measured in a total of 95 acutely depressed patients before and after four weeks of LA...
October 5, 2017: Journal of Psychiatric Research
keyword
keyword
74573
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"